Guard Therapeutics International AB (publ) (STO:GUARD)
Sweden · Delayed Price · Currency is SEK 0.9640
-0.0640 (-6.23%)
Apr 24, 2026, 5:29 PM CET
Guard Therapeutics International AB Earnings Call Transcripts
Fiscal Year 2025
-
The POINTER phase 2B study of RMC-035 in heart surgery patients did not meet its primary or secondary endpoints, showing no significant benefit over placebo and contrasting with prior AKITA results. Strategic review and full data analysis are ongoing, with likely discontinuation of RMC-035 in this indication.
-
A late-stage kidney disease program is nearing key phase 2B data, with strong prior results and FDA fast track status. The company is preparing for phase 3, exploring partnerships, and expects significant commercial and regulatory milestones in the coming months.